AstraZeneca: Tagrisso Approved in China as 1st-Line Treatment

Date : 09/04/2019 @ 6:55AM
Source : Dow Jones News
Stock : Astrazeneca Plc (AZN)
Quote : 7306.0  60.0 (0.83%) @ 4:29PM
Astrazeneca share price Chart

AstraZeneca: Tagrisso Approved in China as 1st-Line Treatment

Astrazeneca (LSE:AZN)
Historical Stock Chart

6 Months : From Jun 2019 to Dec 2019

Click Here for more Astrazeneca Charts.
   By Carlo Martuscelli 

AstraZeneca PLC (AZN.LN) said Wednesday that China's medicines watchdog has approved the use of its drug Tagrisso as a first-line treatment for nonsmall cell lung cancer.

The U.K. pharmaceutical company said the medicine has been approved for patients with locally-advanced or metastatic cancer, and with tumors that showed certain genetic mutations, based on positive results from the phase 3 Flaura trial.

In the trial, Tagrisso used as a primary therapy was able to increase the amount of time patients lived without dying, or without having the disease progress, by a median of 18.9 months, versus 10.2 months for those being administered a standard alternative treatment.

Tagrisso was first approved in China in 2017 as a second-line treatment. With this approval, it will be able to be administered sooner after a patient is diagnosed.


Write to Carlo Martuscelli at


(END) Dow Jones Newswires

September 04, 2019 02:40 ET (06:40 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:us D:20191211 23:23:25